Praxis Precision Medicines (PRAX) Stock Forecast, Price Target & Predictions
PRAX Stock Forecast
Praxis Precision Medicines stock forecast is as follows: an average price target of $145.83 (represents a 143.54% upside from PRAX’s last price of $59.88) and a rating consensus of 'Buy', based on 7 wall street analysts offering a 1-year stock forecast.
PRAX Price Target
The average price target for Praxis Precision Medicines (PRAX) is $145.83 based on 1-year price targets from 7 Wall Street analysts in the past 3 months, with a price target range of $170.00 to $120.00. This represents a potential 143.54% upside from PRAX's last price of $59.88.
PRAX Analyst Ratings
According to 7 Wall Street analysts, Praxis Precision Medicines's rating consensus is 'Buy'. The analyst rating breakdown for PRAX stock is 0 'Strong Buy' (0.00%), 7 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Praxis Precision Medicines Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Sep 04, 2024 | Douglas Tsao | H.C. Wainwright | $120.00 | $58.18 | 106.26% | 100.40% |
| Sep 04, 2024 | Ami Fadia | Needham | $151.00 | $58.18 | 159.54% | 152.17% |
| Sep 03, 2024 | Francois Brisebois | Oppenheimer | $143.00 | $55.38 | 158.22% | 138.81% |
| Sep 03, 2024 | Joon Lee | Truist Financial | $150.00 | $53.95 | 178.01% | 150.50% |
| Aug 14, 2024 | Ami Fadia | Needham | $145.00 | $51.26 | 182.87% | 142.15% |
| Aug 14, 2024 | Yatin Suneja | Guggenheim | $170.00 | $52.24 | 225.42% | 183.90% |
| Aug 05, 2024 | Francois Brisebois | Oppenheimer | $134.00 | $53.52 | 150.37% | 123.78% |
| May 28, 2024 | Kambiz Yazdi | Jefferies | $141.00 | $44.08 | 219.87% | 135.47% |
| Mar 26, 2024 | Kambiz Yazdi | Jefferies | $128.00 | $62.18 | 105.85% | 113.76% |
The latest Praxis Precision Medicines stock forecast, released on Sep 04, 2024 by Douglas Tsao from H.C. Wainwright, set a price target of $120.00, which represents a 106.26% increase from the stock price at the time of the forecast ($58.18), and a 100.40% increase from PRAX last price ($59.88).
Praxis Precision Medicines Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | 4 | 7 | 9 |
| Avg Price Target | $141.00 | $144.71 | $142.44 |
| Last Closing Price | $59.88 | $59.88 | $59.88 |
| Upside/Downside | 135.47% | 141.67% | 137.88% |
In the current month, the average price target of Praxis Precision Medicines stock is $141.00, according to 4 Wall Street analysts offering twelve months forecast. The average price target represents a 135.47% increase as opposed to Praxis Precision Medicines's last price of $59.88. This month's average price target is down -2.56% compared to last quarter, and down -1.01% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 04, 2024 | Wedbush | Buy | Buy | Hold |
| Sep 04, 2024 | Piper Sandler | Underperform | Underperform | Hold |
| Sep 04, 2024 | Needham | Buy | Buy | Hold |
| Sep 04, 2024 | H.C. Wainwright | Buy | Buy | Hold |
| Sep 03, 2024 | Oppenheimer | Outperform | Outperform | Hold |
| Sep 03, 2024 | Cowen & Co. | Buy | Buy | Hold |
| Aug 21, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Aug 14, 2024 | Guggenheim | Buy | Buy | Hold |
| Aug 14, 2024 | Wedbush | Neutral | Neutral | Hold |
| Aug 14, 2024 | H.C. Wainwright | Buy | Buy | Hold |
Praxis Precision Medicines's last stock rating was published by Wedbush on Sep 04, 2024. The company gave PRAX a "Buy" rating, the same as its previous rate.
Praxis Precision Medicines Financial Forecast
Praxis Precision Medicines Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $276.17K | $276.17K | $276.17K | $276.17K | $417.44K | $328.56K | $931.22K | $1.88M | $300.00K |
| High Forecast | $276.17K | $276.17K | $276.17K | $276.17K | $417.44K | $464.94K | $931.22K | $1.88M | $300.00K |
| Low Forecast | $276.17K | $276.17K | $276.17K | $276.17K | $417.44K | $223.17K | $931.22K | $1.88M | $300.00K |
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 3 |
| Surprise % | - | - | - | - | - | - | - | - | - |
Praxis Precision Medicines's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PRAX's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Praxis Precision Medicines EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 3 |
| EBITDA | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $165.70K | $165.70K | $165.70K | $165.70K | $250.47K | $197.13K | $558.73K | $1.13M | $180.00K |
| High Forecast | $165.70K | $165.70K | $165.70K | $165.70K | $250.47K | $278.96K | $558.73K | $1.13M | $180.00K |
| Low Forecast | $165.70K | $165.70K | $165.70K | $165.70K | $250.47K | $133.90K | $558.73K | $1.13M | $180.00K |
| Surprise % | - | - | - | - | - | - | - | - | - |
undefined analysts predict PRAX's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Praxis Precision Medicines's previous annual EBITDA (undefined) of $NaN.
Praxis Precision Medicines Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 3 |
| Net Income | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-41.30M | $-41.98M | $-39.68M | $-36.86M | $-38.49M | $-37.44M | $-43.58M | $-39.21M | $-57.45M |
| High Forecast | $-41.30M | $-41.98M | $-39.68M | $-36.86M | $-38.49M | $-32.41M | $-43.58M | $-39.21M | $-51.97M |
| Low Forecast | $-41.30M | $-41.98M | $-39.68M | $-36.86M | $-38.49M | $-41.35M | $-43.58M | $-39.21M | $-65.47M |
| Surprise % | - | - | - | - | - | - | - | - | - |
Praxis Precision Medicines's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PRAX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Praxis Precision Medicines SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 3 |
| SG&A | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $1.17M | $1.17M | $1.17M | $1.17M | $1.77M | $1.39M | $3.95M | $7.98M | $1.27M |
| High Forecast | $1.17M | $1.17M | $1.17M | $1.17M | $1.77M | $1.97M | $3.95M | $7.98M | $1.27M |
| Low Forecast | $1.17M | $1.17M | $1.17M | $1.17M | $1.77M | $945.61K | $3.95M | $7.98M | $1.27M |
| Surprise % | - | - | - | - | - | - | - | - | - |
Praxis Precision Medicines's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PRAX last annual SG&A of $NaN (undefined).
Praxis Precision Medicines EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 4 | 5 | 2 | 2 | 3 | 7 | 3 | 1 | 3 |
| EPS | - | - | - | - | - | - | - | - | - |
| Avg Forecast | $-2.19 | $-2.23 | $-2.11 | $-1.96 | $-2.04 | $-1.99 | $-2.31 | $-2.08 | $-3.05 |
| High Forecast | $-2.19 | $-2.23 | $-2.11 | $-1.96 | $-2.04 | $-1.72 | $-2.31 | $-2.08 | $-2.76 |
| Low Forecast | $-2.19 | $-2.23 | $-2.11 | $-1.96 | $-2.04 | $-2.20 | $-2.31 | $-2.08 | $-3.48 |
| Surprise % | - | - | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Praxis Precision Medicines's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PRAX previous annual EPS of $NaN (undefined).
Praxis Precision Medicines Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PMVP | PMV Pharmaceuticals | $1.51 | $24.75 | 1539.07% | Buy |
| IMRX | Immuneering | $2.02 | $17.50 | 766.34% | Buy |
| ANTX | AN2 Therapeutics | $1.04 | $8.75 | 741.35% | Buy |
| MOLN | Molecular Partners | $5.22 | $29.00 | 455.56% | Buy |
| PEPG | PepGen | $9.48 | $29.50 | 211.18% | Buy |
| ANEB | Anebulo Pharmaceuticals | $2.08 | $6.00 | 188.46% | Buy |
| MLYS | Mineralys Therapeutics | $11.76 | $30.00 | 155.10% | Buy |
| EWTX | Edgewise Therapeutics | $18.83 | $48.00 | 154.91% | Buy |
| PRAX | Praxis Precision Medicines | $59.88 | $145.83 | 143.54% | Buy |
| STOK | Stoke Therapeutics | $14.47 | $33.75 | 133.24% | Buy |
| PHVS | Pharvaris | $20.92 | $38.50 | 84.03% | Buy |
| CGEM | Cullinan Oncology | $17.95 | $32.00 | 78.27% | Buy |
| ELYM | Eliem Therapeutics | $8.46 | $13.00 | 53.66% | Buy |
| ELVN | Enliven Therapeutics | $22.32 | $33.00 | 47.85% | Buy |
| CRNX | Crinetics Pharmaceuticals | $53.80 | $70.14 | 30.37% | Buy |
| DYN | Dyne Therapeutics | $34.06 | $43.88 | 28.83% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $43.70 | $51.20 | 17.16% | Buy |
PRAX Forecast FAQ
Is Praxis Precision Medicines a good buy?
Yes, according to 7 Wall Street analysts, Praxis Precision Medicines (PRAX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 100.00% of PRAX's total ratings.
What is PRAX's price target?
Praxis Precision Medicines (PRAX) average price target is $145.83 with a range of $120 to $170, implying a 143.54% from its last price of $59.88. The data is based on 7 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Praxis Precision Medicines stock go up soon?
According to Wall Street analysts' prediction for PRAX stock, the company can go up by 143.54% (from the last price of $59.88 to the average price target of $145.83), up by 183.90% based on the highest stock price target, and up by 100.40% based on the lowest stock price target.
Can Praxis Precision Medicines stock reach $90?
PRAX's average twelve months analyst stock price target of $145.83 supports the claim that Praxis Precision Medicines can reach $90 in the near future.
What is Praxis Precision Medicines's current price target trend?
4 Wall Street analysts forecast a $141 price target for Praxis Precision Medicines (PRAX) this month, up 135.47% from its last price of $59.88. Compared to the last 3 and 12 months, the average price target increased by 141.67% and increased by 137.88%, respectively.
What are Praxis Precision Medicines's analysts' financial forecasts?
Praxis Precision Medicines's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $3.56M (high $3.7M, low $3.46M), average EBITDA is $2.14M (high $2.22M, low $2.07M), average net income is $-159M (high $-154M, low $-163M), average SG&A $15.09M (high $15.66M, low $14.64M), and average EPS is $-8.432 (high $-8.164, low $-8.639). PRAX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $1.1M (high $1.1M, low $1.1M), average EBITDA is $662.8K (high $662.8K, low $662.8K), average net income is $-160M (high $-160M, low $-160M), average SG&A $4.68M (high $4.68M, low $4.68M), and average EPS is $-8.49 (high $-8.49, low $-8.49).
Did the PRAX's actual financial results beat the analysts' financial forecasts?
Based on Praxis Precision Medicines's last annual report (Dec 2023), the company's revenue was $2.45M, beating the average analysts forecast of $300K by 715.67%. Apple's EBITDA was $-126M, missing the average prediction of $180K by -70307.22%. The company's net income was $-123M, beating the average estimation of $-57.446M by 114.60%. Apple's SG&A was $42.05M, beating the average forecast of $1.27M by 3208.33%. Lastly, the company's EPS was $-0.0187, missing the average prediction of $-3.052 by -99.39%.